These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 1707983)

  • 1. Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants.
    Saiz JC; Gonzalez MJ; Borca MV; Sobrino F; Moore DM
    J Virol; 1991 May; 65(5):2518-24. PubMed ID: 1707983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus.
    Baxt B; Vakharia V; Moore DM; Franke AJ; Morgan DO
    J Virol; 1989 May; 63(5):2143-51. PubMed ID: 2467993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of virus neutralizing epitopes on naturally occurring variants of type A12 foot-and-mouth disease virus.
    Moore DM; Vakharia VN; Morgan DO
    Virus Res; 1989 Dec; 14(4):281-95. PubMed ID: 2483013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse.
    Barnett PV; Samuel AR; Pullen L; Ansell D; Butcher RN; Parkhouse RM
    J Gen Virol; 1998 Jul; 79 ( Pt 7)():1687-97. PubMed ID: 9680132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epitope mapping of foot-and-mouth disease virus with neutralizing monoclonal antibodies.
    Bolwell C; Clarke BE; Parry NR; Ouldridge EJ; Brown F; Rowlands DJ
    J Gen Virol; 1989 Jan; 70 ( Pt 1)():59-68. PubMed ID: 2471783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic sites on foot-and-mouth disease virus type A10.
    Thomas AA; Woortmeijer RJ; Puijk W; Barteling SJ
    J Virol; 1988 Aug; 62(8):2782-9. PubMed ID: 2455819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the epitope dominance on the capsid of a serotype SAT2 foot-and-mouth disease virus by mutational analyses.
    Opperman PA; Rotherham LS; Esterhuysen J; Charleston B; Juleff N; Capozzo AV; Theron J; Maree FF
    J Virol; 2014 Aug; 88(15):8307-18. PubMed ID: 24829347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence analysis of monoclonal antibody resistant mutants of type O foot and mouth disease virus: evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites.
    Kitson JD; McCahon D; Belsham GJ
    Virology; 1990 Nov; 179(1):26-34. PubMed ID: 1699353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites.
    Xie QC; McCahon D; Crowther JR; Belsham GJ; McCullough KC
    J Gen Virol; 1987 Jun; 68 ( Pt 6)():1637-47. PubMed ID: 2438378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host cell selection of antigenic variants of foot-and-mouth disease virus.
    Bolwell C; Brown AL; Barnett PV; Campbell RO; Clarke BE; Parry NR; Ouldridge EJ; Brown F; Rowlands DJ
    J Gen Virol; 1989 Jan; 70 ( Pt 1)():45-57. PubMed ID: 2471782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization antigenic sites on type Asia-1 foot-and-mouth disease virus defined by monoclonal antibody-resistant variants.
    Butchaiah G; Morgan DO
    Virus Res; 1997 Dec; 52(2):183-94. PubMed ID: 9495534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of neutralizing epitopes on foot-and-mouth disease virus.
    Pfaff E; Thiel HJ; Beck E; Strohmaier K; Schaller H
    J Virol; 1988 Jun; 62(6):2033-40. PubMed ID: 2835507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites.
    Barnett PV; Ouldridge EJ; Rowlands DJ; Brown F; Parry NR
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1483-91. PubMed ID: 2471811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amino acid changes outside the G-H loop of capsid protein VP1 of type O foot-and-mouth disease virus confer resistance to neutralization by antipeptide G-H serum.
    Krebs O; Ahl R; Straub OC; Marquardt O
    Vaccine; 1993; 11(3):359-62. PubMed ID: 7680514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents.
    Parry NR; Barnett PV; Ouldridge EJ; Rowlands DJ; Brown F
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1493-503. PubMed ID: 2471812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of foot-and-mouth disease virus C3 Resende to immunological pressure exerted in vitro by antiviral polyclonal sera.
    Schiappacassi M; Rieder Rojas E; Carrillo E; Campos R
    Virus Res; 1995 Apr; 36(1):77-85. PubMed ID: 7542827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants.
    Stave JW; Card JL; Morgan DO; Vakharia VN
    Virology; 1988 Jan; 162(1):21-9. PubMed ID: 2827379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C.
    Mateu MG; Martínez MA; Capucci L; Andreu D; Giralt E; Sobrino F; Brocchi E; Domingo E
    J Gen Virol; 1990 Mar; 71 ( Pt 3)():629-37. PubMed ID: 1690261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct repertoire of antigenic variants of foot-and-mouth disease virus in the presence or absence of immune selection.
    Borrego B; Novella IS; Giralt E; Andreu D; Domingo E
    J Virol; 1993 Oct; 67(10):6071-9. PubMed ID: 7690417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for at least four antigenic sites on type O foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody-resistant mutants.
    McCahon D; Crowther JR; Belsham GJ; Kitson JD; Duchesne M; Have P; Meloen RH; Morgan DO; De Simone F
    J Gen Virol; 1989 Mar; 70 ( Pt 3)():639-45. PubMed ID: 2471793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.